TB-500 & MOTS-c: FDA Status After the July 2026 Review
Not every peptide the FDA reviewed in July 2026 earned a favorable vote. Two of the most-researched — TB-500 and MOTS-c — were on the July 23 agenda but were not recommended for the 503A compounding list. Here is where each stands. (Research context only.)
What happened at the July review
The FDA’s advisory committee reviewed seven peptides on July 23–24, 2026 and recommended only BPC-157 and KPV. TB-500 and MOTS-c were considered on the 23rd but did not clear the committee; FDA staff had recommended against all seven, citing gaps in characterization, effectiveness, and safety data. See the full roundup and the vote explainer.
TB-500 status
TB-500, a fragment associated with thymosin beta-4, is one of the most-studied peptides in tissue and recovery research and is frequently examined alongside BPC-157. Its exclusion from the July recommendations does not change its research-use-only status, and more peptides are queued for FDA review before February 2027 — so it is not necessarily a closed case. See the BPC-157 vs TB-500 comparison, or the BPC-157 + TB-500 blend and Wolverine kit.
MOTS-c status
MOTS-c is a mitochondrial-derived peptide of interest in metabolic research. Like TB-500, it was reviewed but not recommended in July and remains research-use-only. Browse related compounds in the full catalog.
What comes next
The committee’s recommendations are non-binding, and the FDA will issue final determinations after review. With more peptides on the docket before February 2027, the picture for TB-500 and MOTS-c may keep evolving.
Research use only. Peptides referenced are for in-vitro laboratory research only, not for human or veterinary use, diagnosis, treatment, or consumption. This is regulatory and general information, not legal, medical, or purchasing advice.
Sources: FDA Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026; RAPS and Drug Topics coverage; STAT, NPR, and Time reporting.
